Real Clinics. Real Patients. Real Oncology.

Clinical Trials

Real-World Study Compares Common Treatment Combos for Metastatic Prostate Cancer

A real-world study found ARPI plus ADT outperformed docetaxel plus ADT for progression-related outcomes in metastatic hormone-sensitive prostate cancer. The results support individualized treatment selection based on patient needs, tolerability, and access.

November 20, 2026
Listen to this
article

Treatment for metastatic hormone-sensitive prostate cancer has evolved considerably, with combination therapies becoming an important part of managing the disease. However, selecting among available treatment options can be challenging, particularly when clinicians must balance effectiveness with tolerability, patient preferences, and access to care.

A study published in JCO Oncology Practice provides additional real-world evidence to inform these decisions.

Researchers evaluated outcomes among 9,141 men in the United States with metastatic hormone-sensitive prostate cancer who received androgen deprivation therapy (ADT) combined with either an androgen receptor pathway inhibitor (ARPI) or docetaxel chemotherapy.

The ARPIs examined included abiraterone, apalutamide, and enzalutamide. Researchers compared progression-free survival, overall survival, progression to metastatic castration-resistant prostate cancer, and the need to begin another treatment.

The analysis found that patients receiving an ARPI combined with ADT experienced better progression-free survival than those receiving docetaxel with ADT. Patients in the ARPI groups were also less likely to progress to castration-resistant disease or require a subsequent treatment during follow-up.

However, overall survival was comparable across the four treatment combinations. Researchers also found no significant differences in progression-free or overall survival among the three ARPI regimens.

These findings provide useful context for treatment discussions, particularly because the analysis reflects outcomes from routine clinical practice rather than a randomized clinical trial.

Importantly, the study relied on US medical and pharmacy claims data, with disease progression assessed through treatment patterns and diagnostic information rather than direct radiographic evaluation. As an observational analysis, the findings may also be influenced by differences in patient characteristics and treatment selection that cannot be fully accounted for.

The results do not establish that one treatment approach is superior for every patient. Additionally, the study did not evaluate darolutamide or newer triplet treatment strategies.

For community oncology providers, the research highlights the importance of individualized treatment planning. Factors such as existing health conditions, potential drug interactions, medication adherence, financial burden, and patient preferences may influence which regimen is most appropriate.

Oncology pharmacists can help assess medication-related risks and support adherence, while nurses and navigators can identify practical barriers that may affect treatment continuity.

The findings also reinforce the importance of evaluating treatment success through multiple measures. Delaying progression and avoiding additional therapy may offer meaningful benefits even when differences in overall survival are not demonstrated.

As prostate cancer treatment options continue to expand, real-world evidence can complement clinical trial findings and support collaborative decision-making across multidisciplinary oncology teams.

Source
Nwogu IB, Kreif N, Khan HM, et al. Real-world comparative effectiveness of abiraterone, apalutamide, enzalutamide, and docetaxel doublets for metastatic hormone-sensitive prostate cancer. JCO Oncol Pract. Published online October 1, 2026.

Share this article

Oncology is evolving.
  Stay current.  

Weekly breakthroughs, expert insights, and clinical updates —delivered to your inbox.

Further Reading

What are you
looking for?

POPULAR SEARCHES